Urology Annals

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 6  |  Issue : 1  |  Page : 18--22

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?


Vijay M Patil1, Vanita Noronha1, Amit Joshi1, Vamshi Muddu1, Bharat Bhosale1, Ganesh Bakshi2, Kumar Prabhash1 
1 Department of Medical Oncology, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, India
2 Department of Surgical Oncology, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, India

Correspondence Address:
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai - 400 012
India

Aim: To report safety and efficacy of chemotherapy incorporating the combination of paclitaxel and platinum in patients with advanced penile carcinoma. Materials and Methods: Retrospective analysis of patient with advanced penile carcinoma undergoing palliative chemotherapy with paclitaxel and platinum combination. The demographic profile, indication of treatment, chemotherapy details, toxicity and survival outcome were noted. Statistical analysis was done for estimation of progression free survival and overall survival. Factors affecting these outcomes were sought for. Results: Eighteen patients with a median age of 47.5 years (31-68 years) were offered palliative intent chemotherapy over a period of 2.5 years. ECOG performance was 1 in 12 patients (66.7%) and 2 in 6 patients (33.3%).The grade of tumor was poorly differentiated in 8 patients (44.4%), moderately differentiated in 5 (27.8%) and we1l differentiated in 5 patients (27.8%). Twelve patients had previous surgical treatment (66.7%), with 2 of them having received groin radiation in past. The indication for treatment was metastatic disease in 7 patients (38.9%) and locally advanced disease in 11 patients (61.1%). Out of 18 patients 13 received chemotherapy. Paclitaxel and carboplatin combination was given in 10 patients (76.9%) while paclitaxel and cisplatin was received by 3 patients (23.1%). The median numbers of cycles received were 3 (1-6 cycles). Response rate was 30.8%. The median estimated progression free survival (PFS) and overall survival (OS) for patients receiving atleast one cycle of chemotherapy (n = 13) were 96 days and 246 days respectively. Among tested variables the median OS in patients who had received 2 or more cycles was 351 days versus 55 days in those who received less than 2 cycles (P = 0.025). However, after applying Bonferroni correction, the difference was no longer significant. There was no toxicity related death or life threatening complication. Conclusion: Our institutional protocol of platinum-based doublet with paclitaxel is effective, well-tolerated and has the advantage being delivered on an outpatient basis alone. Overall, we believe that paclitaxel-platinum is an effective regimen that needs to be investigated further in larger studies.


How to cite this article:
Patil VM, Noronha V, Joshi A, Muddu V, Bhosale B, Bakshi G, Prabhash K. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?.Urol Ann 2014;6:18-22


How to cite this URL:
Patil VM, Noronha V, Joshi A, Muddu V, Bhosale B, Bakshi G, Prabhash K. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?. Urol Ann [serial online] 2014 [cited 2021 Jan 21 ];6:18-22
Available from: https://www.urologyannals.com/article.asp?issn=0974-7796;year=2014;volume=6;issue=1;spage=18;epage=22;aulast=Patil;type=0